Lysogene, a Paris, Germany-based gene therapy company, raised €16.5m in Series A funding.
The round was led by Sofinnova Partners, with participation from Bpifrance‘s Innobio fund and Novo Seeds, which is part of Novo A/S. In conjunction with the funding, Rafaèle Tordjman of Sofinnova Partners, Chahra Louafi of Innobio and Henrijette Richter of Novo A/S will join Lysogene’s board.
The company intends to use the funds to expand the clinical studies for its main product developed for patients with Sanfilippo syndrome Type A, towards its marketing approval in Europe and the US, and expand the pipeline with a second product.
Founded in 2009 by Karen Aiach, CEO, and Professor Olivier Danos, Scientific Advisor, an internationally renowned gene therapy scientist, Lysogene is a gene therapy biotechnology company focused on the development of treatments for severe genetic pathologies with central nervous system involvement. The company specilizes in intracerebral gene therapy aimed at treating neuro-degenerative diseases, such as Sanfilippo syndrome Type A, an extremely severe and debilitating disorder which is fatal in childhood and affects approximately 1 in 100,000 births.
Sanfilippo syndrome is a lysosomal storage disease stemming from a deficiency in a particular enzyme, for which there is currently no treatment. In 2013, LYSOGENE completed a phase I-II study (Eudract 2010-019962-10 / NCT01474343) using its lead product in Sanfilippo patients.